Publication

Article

An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer

ON FEBRUARY 3, 2024, a select multidisciplinary group of physicians that included surgeons, radiation oncologists, and medical oncologists from academic and community practices participated in a live workshop to discuss current practices and recent updates on ADCs for the treatment of patients with NSCLC. A discussion moderated by Ticiana Leal, MD, provided perspectives and insights on approved and emerging ADCs in NSCLC including key clinical trial data on ADC efficacy and safety, treatment selection, and strategies to manage associated adverse events (AEs). Leal also presented patient cases for discussion.

Related Videos
Sandip P. Patel, MD
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.